A critical component of the cellular stress response, the p53 tumor suppressor protein must be functional for many cancer therapies to be effective. Adjuvant therapies that augment p53 function are predicted to sensitize tumor cells to cancer therapies that rely upon p53 for their efficacy. Of those strategies currently being explored to enhance p53 function, inhibition of the ubiquitin ligase, MDM2, a negative regulator of p53, has shown promise. Here, we investigated whether MDM2 antagonism might be effective in inducing cell death in human medulloblastoma (MB) cells. Nutlin-3, a small-molecule inhibitor of MDM2, potently induced apoptosis in MB cells with wild-type TP53. Moreover, nutlin-3 potentiated p53 activation and growth impairment of MB cells in combination with the classic DNA-damaging agent doxorubicin. Together, these results support the concept that MDM2 antagonists may be therapeutically beneficial for patients with MB tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2012.02.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Azomethine Derivative, BCS3, Targets XIAP and cIAP1/2 to Arrest Breast Cancer Progression Through MDM2-p53 and Bcl-2-Caspase Signaling Modulation.
Pharmaceuticals (Basel)
December 2024
Department of Biochemistry, School of Medicine, Case Western Reserve University, Woods Building, W437, 2109 Adelbert Road, Cleaveland, OH 44106, USA.
: Breast cancer influences more than 2 million women worldwide annually. Since apoptotic dysregulation is a cancer hallmark, targeting apoptotic regulators encompasses strategic drug development for cancer therapy. One such class of apoptotic regulators is inhibitors of apoptosis proteins (IAP) which are a class of E3 ubiquitin ligases that actively function to support cancer growth and survival.
View Article and Find Full Text PDFTargeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy.
Cells
June 2024
Department of Life and Consumer Sciences, University of South Africa, Cnr Pioneer Road and Christiaan de Wet Road, Florida, Johannesburg 1710, South Africa.
Hdm2 and Hdm4 are structural homologs that regulate the tumor suppressor protein, p53. Since some tumors express wild-type p53, Hdm2 and Hdm4 are plausible targets for anticancer drugs, especially in tumors that express wild-type p53. Hdm4 can enhance and antagonize the activity of Tp53, thereby playing a critical role in the regulation of p53's activity and stability.
View Article and Find Full Text PDFARTS and small-molecule ARTS mimetics upregulate p53 levels by promoting the degradation of XIAP.
Apoptosis
August 2024
Cell Death and Cancer Research Laboratory, Department of Human Biology and Medical Sciences, University of Haifa, 31905, Haifa, Israel.
Mutations resulting in decreased activity of p53 tumor suppressor protein promote tumorigenesis. P53 protein levels are tightly regulated through the Ubiquitin Proteasome System (UPS). Several E3 ligases were shown to regulate p53 stability, including MDM2.
View Article and Find Full Text PDFCombination p53 activation and BCL-x/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia
June 2024
Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Article Synopsis
- TP53 mutations are rare in acute lymphoblastic leukemia (ALL), making the MDM2 antagonist idasanutlin a promising treatment option for most ALL cases.
- Combining idasanutlin with the BCL-x/BCL-2 inhibitor navitoclax has shown significant antileukemic effects in laboratory models, leading to a synergistic reduction in leukemia cell viability.
- These findings highlight the potential of using both drugs together in treating high-risk and relapsed ALL patients, with the combination demonstrating effectiveness at safe drug concentration levels seen in clinical trials.
Pseudorabies virus inhibits progesterone-induced inactivation of TRPML1 to facilitate viral entry.
PLoS Pathog
January 2024
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, Henan Province, China.
Article Synopsis
- - Viral infections, particularly from neurotropic alphaherpesviruses like pseudorabies virus (PRV), can negatively affect female fertility by disrupting the hypothalamus-pituitary-ovary axis (HPOA) and reducing progesterone levels, leading to lower pregnancy rates.
- - The study found that PRV uses the transient receptor potential mucolipin 1 (TRPML1) and a specific lipid, phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2), to aid its entry into cells, compromising cellular health.
- - Progesterone (P4) acts to counter this viral invasion by causing lysosomal storage disorders and promoting the degradation of
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!